A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Camrelizumab, Famitinib.
- Who it may be relevant to
- Registry conditions: Cervical Cancer Metastatic, Cervical Cancer Recurrent. Basic parameters: from 18 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This trial is a national multicenter, open-label, non-interventional study to observe and evaluate the safety and efficacy of monotherapy or combination regimens based on camrelizumab or famitinib in patients with cervical cancer. This study included patients with cervical cancer who used monotherapy or combination regimens based on camrelizumab or famitinib. The administration regimens include but are not limited to camrelizumab monotherapy, camrelizumab in combination with mitinib, famitinib monotherapy, camrelizumab in combination with other treatment regimens selected by the investigator, camrelizumab in combination with mitinib and other treatment regimens selected by the investigator, and famitinib in combination with other treatment regimens selected by the investigator. It is planned to include cervical cancer patients who have decided to be treated with monotherapy or combination regimens based on camrelizumab or famitinib before enrollment, with an estimated 1,300 cases. According to the treatment plan received by the patients, after enrollment, they can be respectively placed in one of the following six cohorts: Queue 1: Only receiving camrelizumab monotherapy Queue 2: Only receiving famitinib monotherapy Queue 3: Only combination therapy of camrelizumab and famitinib was received Queue 4: Receiving camrelizumab in combination with other treatment regimens Queue 5: Receiving famitinib in combination with other treatment regimens Queue 6: Receiving camrelizumab and famitinib in combination with other treatment regimens Data from the baseline period, treatment period and follow-up period were collected respectively according to the cohort category (prospective or retrospective) of the enrolled patients.
Interventions
- Drug Camrelizumab
200mg IV Q3W - Drug Famitinib
20mg QD PO
Primary outcome measures
- safety according to CTCAE v5.0 [Time frame: From the first administration to 30 days after the end of the medication]
Secondary outcome measures (2)
- real world ORR [Time frame: from the initiation of monotherapy or combination regimens, per 6-8 weeks]
- overall survival [Time frame: From date of treatment until the date of date of death from any cause, assessed up to 3 years]
Eligibility criteria
Inclusion criteria
- Age ≥18 years old;
- Sign the informed consent form and voluntarily join this study;
- Patients with cervical cancer diagnosed by histopathology;
- Receive treatment with monotherapy or combination regimens based on camrelizumab or famitinib;
- It is necessary to agree to take effective contraceptive measures and avoid egg donation from the time of signing the informed consent form until 2 months after the last administration of camrelizumab, 3 months after the last administration of famitinib, or within the contraceptive period specified in the instructions of the last administration of other study drugs (whichever is longer).
If a patient has had menstruation but has not yet reached postmenopausal status (with no menstruation for a continuous period of ≥12 months and no other causes found except menopause), and has not undergone sterilization surgery (such as hysterectomy, bilateral tubal ligation or bilateral oophorectomy), the patient is considered to have fertility.
Exclusion criteria
- There is already evidence indicating that the patient is a pregnant or lactating woman.
- Currently participating in any research involving intervention measures outside of regular clinical practice;
- The researcher determines other circumstances that are not suitable for inclusion in the study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07266350 · CZLL2025-042-001